Pre-symbiotic response of the compatible host spruce and low-compatibility host pine to the ectomycorrhizal fungus Tricholoma vaccinum
Mutualistic ectomycorrhizal symbiosis requires the exchange of signals even before direct contact of the partners. Volatiles, and specifically volatile terpenoids, can be detected at a distance and may trigger downstream signaling and reprogramming of metabolic responses. The late-stage ectomycorrhizal fungus Tricholoma vaccinum shows high host specificity with its main host spruce, Picea abies, while rarely associations can be found with pine, Pinus sylvestris. Hence, a comparison of the host and the low-compatibility host’s responses can untangle differences in early signaling during mycorrhiza formation. We investigat...
Source: Frontiers in Microbiology - December 4, 2023 Category: Microbiology Source Type: research
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
CONCLUSION: In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.PMID:38043782 | DOI:10.4093/dmj.2023.0171 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Jun Sung Moon Il Rae Park Sang Soo Kim Hye Soon Kim Nam Hoon Kim Sin Gon Kim Seung Hyun Ko Ji Hyun Lee Inkyu Lee Bo Kyeong Lee Kyu Chang Won Source Type: research
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
CONCLUSION: In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.PMID:38043782 | PMC:PMC10695717 | DOI:10.4093/dmj.2023.0171 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Jun Sung Moon Il Rae Park Sang Soo Kim Hye Soon Kim Nam Hoon Kim Sin Gon Kim Seung Hyun Ko Ji Hyun Lee Inkyu Lee Bo Kyeong Lee Kyu Chang Won Source Type: research
